Cardiovascular disease in chronic obstructive pulmonary disease

Proceedings of the American Thoracic Society

Volumn 2, Issue 1, 2005, Pages 44-49

  Hunninghake, Donald B ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Cardiovascular disease; Cholesterol; COPD; Statin; Therapy

Indexed keywords

ACUTE PHASE PROTEIN; ATORVASTATIN; C REACTIVE PROTEIN; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PRAVASTATIN; PROSTACYCLIN; SIMVASTATIN;

AGE DISTRIBUTION; ARTERY DISEASE; AWARENESS; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DYSLIPIDEMIA; ENDOTHELIUM LESION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; OXIDATIVE STRESS; PLEIOTROPY; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING; THROMBOSIS; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CYTOKINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING;

EID: 17644383005     PISSN: 15463222     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1513/pats.200410-050SF     Document Type: Conference Paper

References (27)

1. Ross R. Atherosclerosis, an inflammatory disease. N Engl J Med 1999;140: 115-126.
2. Libby P. The vascular biology of atherosclerosis in heart disease. In: Braunwald E, editor. A textbook of cardiovascular medicine, 6th ed. Philadelphia: W.B. Saunders; 2001. pp. 995-1010.
3. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
4. Kinlay S, Selwyn AP. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol 2003;91:9B-13B.
5. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanism. Eur Respir J 2003;22:672-688.
6. Ondijk EJ, Lammers SW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J 2003;(Suppl 46): 59-133.
7. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
8. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-1519.
9. Lind P, Engstrom G, Stavenow L, Janzon L, Lindgarde F, Hedblad B. Risk of myocardial infarction and stroke in smokers is related to plasma levels of inflammation-sensitive proteins. Arterioscler Thromb Vasc Biol 2004;24:577-582.
10. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). ATP III Final report. Circulation 2002; 106:31-45.
11. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
12. Scandinavian Simvastatin Survival Study. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease. Lancet 1994; 244:1383-1389.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,953 people with diabetes: a randomized placebo-controlled trial. Lancet 2003;361:2005-2016.
15. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.
16. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statin after acute coronary syndromes. N Engl J Med 2004;350:1485-1504.
17. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, et al., for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2004;361:1149-1158.
18. Ashley F, Kannel WB, Sorlic PD, Mason R. Pulmonary function: relationships to aging, cigarette habit and mortality. The Framingham Study. Ann Intern Med 1975;82:739-745.
19. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow-up study. Thorax 2003;58:388-393.
20. Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H. Relations of plasma, high-sensitivity, C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003;167:73-79.
21. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelets and vascular function in healthy individuals who smoke cigarettes. Circulation 1987;76:6-14.
22. Villablanca AC, McDonald JM, Rutledge JC. Smoking and cardiovascular disease. Clin Chest Med 2000;21:159-172.
23. Craig WY, Palomadi GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentration: an analysis of published data. BMJ 1989;289:784-792.
24. Expert Panel Writing Group. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672-693.
25. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1253.
26. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27:515-535.
27. Croxton TL, Weinmann GG, Senior RM, Wise RA, Crapo JD, Buist AS. NHLBI workshop summary: clinical research in chronic obstructive pulmonary disease: needs and opportunities. Am J Respir Crit Care Med 2003;167:1142-1149.